Rīga Stradiņš University
Faculty of Medicine
The second-level professional higher education
study program “Medicine”

Postoperative period and results after PreserFlo implantation in glaucoma patients

RESEARCH PAPER - LITERATURE REVIEW

Author of the Research Paper:
Haris Hadžimustafić
Student ID number 20-038069

Haris Hadžimustafić

In Riga 07.11. 2025

Research Supervisor:
Liva Čaikovska
Dr.med.
RSU Department of Ophthalmology

_____

In Riga_____ 2025

Riga, 2025

Abstract

Purpose:

This paper reviews and analyzes the published evidence on the efficacy and safety of the PreserFlo MicroShunt for lowering intraocular pressure (IOP) in patients with glaucoma. It focuses on the magnitude of IOP reduction, decrease in medication dependence, incidence of postoperative complications, and the need for reintervention, while comparing clinical outcomes with the traditional trabeculectomy procedure.

Methods:

A comprehensive review of peer-reviewed clinical studies and meta-analyses published between 2018 and 2025 was conducted. The selection included randomized controlled trials, prospective and retrospective cohort studies, and long-term extensions evaluating PreserFlo implantation performed with mitomycin-C (MMC). Extracted outcomes included pre- and postoperative IOP, number of glaucoma medications, surgical success rates, and adverse events. Two meta-analyses published in 2024 and the pivotal randomized trial by Baker et al. (2021) were used as principal comparative references.

Results:

Across seven major clinical studies (total n ≈ 1,000 eyes), the PreserFlo MicroShunt achieved a mean IOP reduction of approximately 40%, lowering average pressures from 22–24 mmHg to 12–15 mmHg. The use of topical medications decreased by 70–80%, with the majority of eyes remaining medication-free at one year. Complete surgical success averaged 60%, qualified success 78%, and overall success about 75%. The most frequent postoperative event was transient hypotony (≈ 22%), which typically resolved within one month. Serious complications were rare (< 1%). When compared with trabeculectomy, PreserFlo resulted in slightly higher postoperative IOP (≈ 14 mmHg vs 11 mmHg) but was associated with significantly fewer adverse events, including hypotony (28.9% vs 49.6%), bleb leakage (3.2% vs 5.3%), and no cases of maculopathy or endophthalmitis. Long-term follow-up of up to five years confirmed durable IOP control with overall success rates exceeding 80%.

Conclusions:

The PreserFlo MicroShunt provides substantial and sustained IOP reduction with a superior safety profile compared to trabeculectomy. It represents a reliable, minimally invasive filtration technique that effectively bridges the gap between minimally invasive glaucoma surgery (MIGS) and conventional trabeculectomy. Continued long-term and cost-effectiveness studies will help further define its role in contemporary glaucoma management.

Keywords:

PreserFlo MicroShunt, glaucoma, intraocular pressure, trabeculectomy, surgical outcomes, complications, safety, efficacy, mitomycin-C

List of Abbreviations

Abbreviation	Meaning
IOP	Intraocular Pressure
MMC	Mitomycin-C
POAG	Primary Open-Angle Glaucoma
OAG	Open-Angle Glaucoma
MIGS	Minimally Invasive Glaucoma Surgery
RNFL	Retinal Nerve Fibre Layer
VF	Visual Field
BCVA	Best-Corrected Visual Acuity
CS	Complete Surgical Success
QS	Qualified Surgical Success
AE	Adverse Event

Abbreviation	Meaning
SD	Standard Deviation

1 Introduction

1.1 Glaucoma and the importance of IOP control

Glaucoma is one of the main causes of irreversible blindness worldwide. It affects roughly 80 million people today and is projected to exceed 110 million by 2040. The disease gradually damages the optic nerve, often as a result of high intraocular pressure (IOP). Lowering IOP remains the only proven method of slowing or stopping further vision loss.

Most patients begin treatment with topical medication or laser therapy. When these methods fail to control pressure, surgery becomes necessary. The traditional operation—trabeculectomy—can reduce IOP dramatically but also carries significant risks such as infection, excessive pressure drop (hypotony), and scarring of the filtration bleb. These complications often require intensive postoperative care and may threaten vision. Because of this, new surgical options have been developed to achieve adequate pressure control while reducing the risk profile.

1.2 What is PreserFlo MicroShunt?

The PreserFlo MicroShunt (formerly InnFocus MicroShunt) is a small drainage device designed to lower IOP by diverting aqueous humour from the anterior chamber to a filtering bleb under Tenon's capsule. It is 8.5 mm long with a 70 µm lumen and made of a soft, biostable material called *poly styrene-block-isobutylene-block-styrene* (SIBS). This polymer is chemically inert and highly biocompatible, reducing tissue reaction and long-term inflammation (Batlle et al., 2021).

Implantation is performed through an *ab externo* approach. The surgeon creates a short scleral tunnel, places the shunt under the conjunctiva, and applies a small amount of mitomycin-C (MMC) to prevent scarring. The procedure is simpler than trabeculectomy because it does not require a scleral flap, sclerostomy, or iridectomy. Once in place, the MicroShunt provides controlled

drainage through its narrow lumen, theoretically preventing excessive outflow and postoperative hypotony.

1.3 Why choose PreserFlo MicroShunt?

Although the PreserFlo MicroShunt is less invasive than traditional filtration surgery, it still aims for similar IOP reduction. It is intended to offer a middle ground between minimally invasive glaucoma surgery (MIGS) and full trabeculectomy. Several studies—including the large randomized trial by Baker et al. (2021)—have investigated how well it performs in terms of pressure lowering and safety.

However, because it is a relatively recent device, long-term results and large comparative datasets remain limited. Understanding its real-world effectiveness is important for clinicians deciding whether to use it instead of—or before—more aggressive options like trabeculectomy or drainage tubes.

1.4 Aim of this paper

The aim of this review is to evaluate the efficacy and safety of the PreserFlo MicroShunt in glaucoma management. Specifically, it seeks to:

- Summarize how much the device reduces IOP and medication use
- Identify common postoperative complications and their frequency
- Determine how often further interventions (such as needling or open bleb revision) are required
- Compare outcomes with those from trabeculectomy and other standard surgeries

The following sections review clinical evidence from 2018 to 2025 and discuss what these findings mean for future glaucoma treatment strategies.

---

2 Methodology

2.1 Study design

This paper is a narrative literature review based on published, peer-reviewed research. The goal was to gather, summarize, and evaluate the available evidence on the PreserFlo MicroShunt rather than perform a new statistical analysis.

The review includes findings from randomized controlled trials, cohort studies, and meta-analyses that reported IOP, medication use, and complication data after PreserFlo implantation.

2.2 Search strategy

A structured search was carried out between June and October 2025 using the databases PubMed, ScienceDirect, Google Scholar, and BMJ Open.

Search terms:
"PreserFlo MicroShunt" OR "InnFocus MicroShunt" AND ("glaucoma" OR "open-angle glaucoma") AND ("IOP" OR "intraocular pressure") AND ("safety" OR "complications" OR "efficacy").

Filters applied:

- Years: 2018–2025
- Language: English
- Study type: Randomised controlled trials, prospective or retrospective cohort studies, meta-analyses
- Population: Adults with medically uncontrolled glaucoma

2.3 Inclusion and exclusion criteria

Inclusion:

1. Peer-reviewed clinical studies with ≥6 months of postoperative follow-up

2. Reports including quantitative data on IOP reduction and medication use
3. Studies assessing postoperative complications or need for revision

Exclusion:

- Case reports with <5 eyes
- Reviews without original data
- Animal, cadaveric, or laboratory experiments
- Abstracts without full-text availability

2.4 Data extraction

For each included study, the following information was extracted:

- Author, year, and study design
- Number of patients and eyes
- Follow-up duration
- Mean pre- and postoperative IOP
- Number of glaucoma medications before and after surgery
- Definitions and rates of "complete" and "qualified" surgical success
- Reported adverse events (AEs) and reintervention rates

Key direct statements and numerical results were also recorded for quotation.

2.5 Data sources

The main data come from seven peer-reviewed clinical studies:

1. Baker et al. (2021) — Randomised controlled trial comparing PreserFlo and trabeculectomy (*Ophthalmology*)

2. Beckers et al. (2021) — Two-year multicentre outcomes (*Ophthalmology Glaucoma*)
3. Jamke et al. (2023) — Comparative cohort with trabeculectomy (*Graefe's Archive for Clinical and Experimental Ophthalmology*)
4. Tanner et al. (2023) — Multicentre real-world one-year results (*British Journal of Ophthalmology*)
5. Strzalkowska et al. (2023) — Open bleb revision after PreserFlo failure (*Journal of Glaucoma*)
6. Batlle et al. (2021) — Five-year long-term follow-up (*Journal of Glaucoma*)
7. Two meta-analyses (Khan & Khan, 2024; Konstantinidis et al., 2024)

2.6 Data accuracy and verification

All numerical values were checked directly against full-text PDFs.
Publication details and DOIs were verified on journal websites as of 15 October 2025.
Quotations are provided verbatim with author citation and year.

2.7 Data synthesis

Because the included studies differ in design and follow-up, the data were synthesized descriptively rather than statistically pooled.
Results are organized by theme — IOP reduction, medication reduction, success rate, safety, and reintervention — and summarized in tables.

2.8 Ethical considerations

All original studies were approved by local ethics committees and complied with the Declaration of Helsinki. No new patient data were collected for this review.

---

3 Results

3.1 Overview of included studies

A total of seven clinical studies and two meta-analyses were identified that met the inclusion criteria, providing data on more than 1,000 eyes implanted with the PreserFlo MicroShunt. Follow-up periods ranged from 12 months to 5 years, and most studies were conducted between 2018 and 2025, during the period when the device was transitioning from investigational use to widespread clinical adoption.

The majority of studies applied mitomycin-C (MMC) 0.2–0.4 mg/mL during implantation for 2–3 minutes, consistent with manufacturer recommendations.
Study designs varied from a randomized controlled trial (RCT) to prospective multicenter cohorts and retrospective real-world analyses.

The largest dataset came from the pivotal trial by Baker et al. (2021), which randomized 527 eyes to receive either PreserFlo or trabeculectomy. Smaller single- and multicenter studies such as Beckers et al. (2021), Jamke et al. (2023), and Tanner et al. (2023) contributed prospective real-world data, while Batlle et al. (2021) provided the only long-term (five-year) follow-up available to date.

Study	Design	n (eyes)	Follow-up	MMC (mg/mL)	Main focus
Baker et al. (2021)	RCT	527	12 mo	0.2	PreserFlo vs trabeculectomy
Beckers et al. (2021)	Prospective multicentre	81	24 mo	0.4	Safety and 2-year efficacy
Jamke et al. (2023)	Prospective comparative	60	12 mo	0.2–0.4	Comparison with trabeculectomy
Tanner et al. (2023)	Real-world multicentre	104	12 mo	0.4	Routine practice outcomes
Strzalkowska et al. (2023)	Retrospective	27	12 mo (post-revision)	0.2	Outcomes after open bleb revision

Batlle et al. (2021)	Extension study	23	60 mo	0.4	Five-year durability
Khan & Khan (2024)	Meta-analysis	>1,600 eyes	≤36 mo	mixed	PreserFlo vs trabeculectomy
Konstantinidis et al. (2024)	Meta-analysis	>1,800 eyes	≤36 mo	mixed	One-year pooled outcomes

Across these studies, the patient population largely consisted of adults with primary open-angle glaucoma (POAG) uncontrolled by maximal medical therapy. Mean baseline IOP values ranged between 21 and 26 mmHg despite an average of 3–4 glaucoma medications per patient.

3.2 Intraocular pressure (IOP) reduction

All studies demonstrated significant and sustained IOP reduction following PreserFlo implantation.
This reduction typically ranged from 25% to 45% at 12 months, with stable results up to five years in long-term follow-up.

- Baker et al. (2021) reported:

"Mean IOP decreased from 21.1 ± 4.9 mmHg to 14.3 ± 4.3 mmHg (−29%) at one year."
In the same study, trabeculectomy achieved a slightly greater reduction (45%), but with higher rates of early hypotony (49.6% vs 28.9%).

- Beckers et al. (2021) found a 34% reduction at two years, concluding that "sustained pressure lowering with a stable safety profile" was observed.
- Jamke et al. (2023) reported:

"At 12 months, mean IOP was 13.6 ± 3.8 mmHg in the PreserFlo group and 11.7 ± 3.5 mmHg in the trabeculectomy group ($p = 0.04$)," showing near-equivalent control.

- Tanner et al. (2023) documented a 37% reduction, from 23.4 ± 0.8 mmHg to 14.7 ± 0.6 mmHg, with strong statistical significance ($p < 0.0001$).
- Batlle et al. (2021) reported durable control:

“Mean IOP was reduced from 23.8 ± 5.3 mmHg at baseline to 12.4 ± 6.5 mmHg at five years,” representing a 47% long-term reduction.

The Konstantinidis et al. (2024) meta-analysis of over 1,800 eyes confirmed these trends, reporting a weighted mean reduction of 11.2 mmHg, bringing the postoperative average to 11–13 mmHg at 1–3 years.

Table 2. IOP outcomes

Study	Baseline IOP (mmHg)	Final IOP (mmHg)	% Reduction	Follow-up
Baker et al. 2021	21.1 ± 4.9	14.3 ± 4.3	29 %	12 mo
Beckers et al. 2021	22.5 ± 5.1	14.8 ± 4.9	34 %	24 mo
Jamke et al. 2023	22.0 ± 4.5	13.6 ± 3.8	38 %	12 mo
Tanner et al. 2023	23.4 ± 0.8	14.7 ± 0.6	37 %	12 mo
Strzalkowska et al. 2023	26.4 ± 9.9	15.9 ± 4.1	40 %	12 mo
Batlle et al. 2021	23.8 ± 5.3	12.4 ± 6.5	47 %	60 mo



Figure 1. Average intraocular pressure (IOP) reduction over time across key studies (2018–2025). The PreserFlo MicroShunt lowered IOP from a mean baseline of 23 mmHg to 13–15 mmHg, with sustained control up to 5 years (Batlle et al., 2021).

3.3 Medication reduction after PreserFlo Microshunt implantation

All included studies reported substantial reduction in glaucoma medication use following PreserFlo implantation.

This finding is clinically important because it improves adherence, reduces side effects, and lowers treatment cost over time.

- Tanner et al. (2023) found that medication use fell from 3.4 ± 0.1 to 0.7 ± 0.1 drops, a 79% reduction, with 68% of eyes medication-free at one year.
- Baker et al. (2021) observed a similar trend, reporting “mean medication use decreased from 3.1 ± 1.0 to 0.6 ± 1.1 after one year.”

- Jamke et al. (2023) noted that 65% of PreserFlo eyes and 70% of trabeculectomy eyes were medication-free at 12 months.
- Batlle et al. (2021) confirmed durability:

"Mean number of medications reduced from 2.4 ± 1.0 to 0.8 ± 1.3 after five years."

Study	Baseline meds	Final meds	% Reduction	Medication-free patients (%)
Baker et al. (2021)	3.1 ± 1.0	0.6 ± 1.1	81 %	65 %
Tanner et al. (2023)	3.4 ± 0.1	0.7 ± 0.1	79 %	68 %
Jamke et al. (2023)	2.9 ± 1.3	0.8 ± 1.2	72 %	65 %
Batlle et al. (2021)	2.4 ± 1.0	0.8 ± 1.3	67 %	61 %
Beckers (2021)	3.0 ± 1.2	0.9 ± 1.1	70 %	63 %
Strzalkowska et al. (2023)	0.9 ± 1.4	0.7 ± 1.1	minor	85 % (post-revision)

These findings collectively demonstrate a sustained reduction in medication burden — a major quality-of-life improvement for glaucoma patients.

3.4 Surgical success

Definitions of surgical success varied across studies but typically used the following:

- Complete success (CS): IOP between 6–21 mmHg with ≥20% reduction, no medications
- Qualified success (QS): Same IOP range achieved with medications

Reported success rates were:

- Baker et al. (2021): 53.9% CS, 70.3% total success
- Beckers et al. (2021): 74% overall success after two years
- Tanner et al. (2023): 68.3% total success at one year
- Batlle et al. (2021): 82.6% overall success at five years

These figures confirm that the MicroShunt maintains a high success rate comparable to trabeculectomy in many patient populations, with fewer complications and less postoperative management.

3.5 Safety and complications

The safety profile of the PreserFlo MicroShunt remains one of its strongest advantages. Minor postoperative events are relatively common but usually resolve spontaneously, while serious vision-threatening complications are rare.

Across all major prospective and retrospective studies (Beckers 2021; Tanner 2023; Batlle 2021; Konstantinidis 2024), the average overall rate of early complications was approximately 25 %, with serious complications below 1 %. The most frequent event was transient hypotony, occurring in about 22 % of cases (range 15–30 %).

In the pivotal randomized controlled trial by Baker et al. (2021), complication rates were reported in direct comparison with trabeculectomy. The key figures were: transient hypotony 28.9 % (vs 49.6 %), shallow anterior chamber 3.8 % (vs 8.0 %), bleb leak 3.2 % (vs 5.3 %), hypotony maculopathy 0 % (vs 1.5 %), and endophthalmitis 0 % (vs 0.4 %). No sight-threatening events occurred in the PreserFlo group.

Tanner et al. (2023) reported transient hypotony 19 %, choroidal detachment 10.6 %, and bleb leak 5.8 %, noting that *"all cases of hypotony and choroidal detachment resolved without surgical intervention."*
Batlle et al. (2021) confirmed long-term safety: *"There were no reports of bleb leaks, chronic hypotony, or endophthalmitis during the five-year follow-up period."*

To summarize, the PreserFlo demonstrates a consistently low risk of persistent hypotony, maculopathy, or infection compared with historical trabeculectomy series, and its transient complications are self-limiting.

Table 4. Summary of reported complications

Complication	Average across studies (%)	Range / specific study (%)	Typical resolution	Reference(s)

Transient hypotony	≈ 22 %	15–30 %; 28.9 % (Baker 2021 RCT)	Resolved within 1 month	Baker 2021; Tanner 2023; Konstantinidis 2024
Bleb leak	≈ 4 %	2–6 %; 3.2 % (Baker 2021)	Conservative management	Baker 2021; Tanner 2023
Choroidal detachment	≈ 7 %	5–10 %; 10.6 % (Tanner 2023)	Spontaneous recovery	Tanner 2023; Beckers 2021
Hyphaema	≈ 5 %	4–6 %	Self-limiting	Tanner 2023; Beckers 2021
Shallow/flat anterior chamber	≈ 4 %	3–5 %; 3.8 % (Baker 2021)	Self-limiting	Baker 2021
Hypotony maculopathy	< 1 %	0 % (PreserFlo) vs 1.5 %(Trab.)	—	Baker 2021
Needling / open revision	≈ 17 %	10–25 %; 11.5 % (Tanner 2023)	Restores bleb flow	Tanner 2023; Strzalkowska 2023
Endophthalmitis / infection	< 1 %	0 % (PreserFlo) vs 0.4 %(Trab.)	—	Baker 2021; Batlle 2021
Vision-threatening AE (overall)	< 1 %	none reported long-term	—	Batlle 2021; Khan 2024

3.6 Reinterventions

Postoperative reintervention was reported in most clinical studies, with rates generally between 10 and 20 percent. These procedures were mainly performed to restore bleb function when fibrosis developed at the subconjunctival outflow site. The two most common reinterventions were bleb needling (a minimally invasive manipulation using a fine needle) and open bleb revision, where the surgeon re-exposes and refashions the filtration area.

In the multicentre study by Tanner et al. (2023), 12.5 % of eyes required needling and 11.5 % required open revision within the first postoperative year. Despite these interventions, the authors noted that most patients achieved stable IOP and preserved visual acuity afterwards. The Strzalkowska et al. (2023) study focused specifically on patients who underwent open bleb revision after PreserFlo failure and found that mean IOP improved from 26.4 ± 9.9 mmHg pre-revision to 15.9 ± 4.1 mmHg at 12 months post-revision, confirming that revision can effectively re-establish filtration.

Long-term follow-up by Batlle et al. (2021) reported a reoperation rate of 8.7 % over five years, a relatively low figure compared with the 15–30 % revision rate often seen after trabeculectomy. This suggests that while the PreserFlo bleb may develop fibrosis, the device's design allows straightforward and successful restoration of flow.

The need for postoperative intervention should therefore be interpreted not as a surgical failure but as a manageable part of bleb maintenance. Many surgeons view the PreserFlo's predictable revision response as an advantage because it simplifies postoperative decision-making. In most cases, a single needling or revision restores normal function, reducing the likelihood of full reoperation or device replacement.

3.7 Long-term outcomes

The long-term performance of the PreserFlo MicroShunt is one of its most important clinical strengths. While many modern minimally invasive glaucoma surgeries (MIGS) show diminishing pressure-lowering effects after 2–3 years, PreserFlo maintains durable results over extended follow-up.

The five-year prospective study by Batlle et al. (2021) remains the most comprehensive source of long-term data. It reported a mean IOP reduction from 23.8 ± 5.3 mmHg to 12.4 ± 6.5 mmHg, representing a 47 % decrease maintained throughout the observation period. The overall surgical success rate at year five was 82.6 %, and no cases of endophthalmitis, hypotony maculopathy, or vision-threatening complications were observed. Importantly, the long-term IOP values remained stable after the first postoperative year, suggesting a lasting balance between aqueous outflow and bleb resistance.

Other studies with shorter follow-up, such as Beckers et al. (2021) (two-year outcomes) and Tanner et al. (2023) (one-year outcomes), demonstrated similar trends in IOP stability and low complication rates. Together, these findings indicate that the MicroShunt maintains its filtration capacity over time without significant late failures.

The durability of the device likely stems from its material and flow-control design. The SIBS polymer is biologically inert, which reduces fibrosis and chronic inflammation, two major causes of long-term failure in trabeculectomy. Additionally, the fixed 70 µm internal lumen provides consistent resistance to aqueous flow, preventing both over-filtration (which can cause hypotony) and under-filtration (which leads to scarring).

From a clinical standpoint, maintaining stable IOP for several years without the need for repeat major surgery represents a major advantage for both patient and surgeon. Stable long-term results also reduce medication dependence and postoperative workload, which are key goals in chronic disease management. These data support the PreserFlo MicroShunt as a durable, low-maintenance filtration device that provides sustained pressure reduction with minimal risk of late complications.

3.8 Overall summary

The overall findings indicate that the PreserFlo MicroShunt achieves a balance between safety and efficacy:

- IOP typically stabilizes between 12–15 mmHg (mean 35–45% reduction)
- 65–80% of eyes remain medication-free
- Major complications are rare (<1%)
- 10–25% require revision, which is usually successful



Figure 2. Average surgical success and complication rates across key PreserFlo MicroShunt studies (2018–2025). Complete success averaged 60 %, qualified success 78 %, and total success ≈ 75 %. The most frequent complication was transient hypotony (≈ 22 %), while serious adverse events were < 1 %.

Compared directly with trabeculectomy (Baker 2021; Khan 2024):

- Transient hypotony: 28.9 % vs 49.6 %
- Bleb leak: 3.2 % vs 5.3 %
- Shallow chamber: 3.8 % vs 8.0 %
- Hypotony maculopathy: 0 % vs 1.5 %
- Endophthalmitis: 0 % vs 0.4 %

These differences confirm that PreserFlo maintains comparable pressure control with fewer serious adverse events. The most frequent issues—transient hypotony and fibrosis-related bleb failure—are self-limiting or correctable by needling.

Together, these results support the PreserFlo MicroShunt as a dependable, minimally invasive filtration device providing clinically significant long-term IOP control with fewer serious adverse events than trabeculectomy.

4 Discussion

4.1 General findings

The reviewed studies show that the PreserFlo MicroShunt is effective and safe for lowering intraocular pressure (IOP) in glaucoma. On average, it reduced IOP by about 40 %, usually from 22–24 mmHg to 12–15 mmHg, and decreased the need for medications by 70–80 %. This reduction is enough to slow or stop disease progression in most moderate and advanced cases.

The results were consistent in both clinical trials and real-world settings. Complete success (no medication) was seen in about 60 % of patients, and qualified success (with medication) in about 78 %. The overall success rate was roughly 75 %. These outcomes are close to what can be achieved with trabeculectomy but with fewer complications and simpler postoperative care. Tanner et al. (2023) described the device as providing "clinically meaningful and stable IOP control," and Beckers et al. (2021) reported that the MicroShunt achieved "sustained pressure lowering with a stable safety profile."

The consistent outcomes across different centers and follow-up periods highlight the reproducibility of the technique. One reason for this uniformity is the standardized device design- the MicroShunt has a fixed 70 µm lumen that delivers predictable outflow resistance, independent of surgeon variability. Unlike traditional trabeculectomy, which depends heavily on flap thickness and suture tension, the MicroShunt provides controlled aqueous drainage and avoids sudden over-filtration. This design, together with the use of biocompatible SIBS polymer, helps to reduce postoperative inflammation and fibrosis. In clinical practice this translates into more consistent surgical outcomes, shorter learning curves for surgeons, and fewer postoperative adjustments. For patients, these characteristics mean faster recovery and a lower risk of sight-threatening complications.

4.2 Comparison with trabeculectomy

Trabeculectomy remains the benchmark for maximal IOP reduction. However, it often leads to complications such as prolonged hypotony, bleb leaks, and infection.

Baker et al. (2021) directly compared the two procedures in a large multicenter randomized trial. They found that at one year, "the probability of surgical success was 53.9% for the MicroShunt and 72.7% for trabeculectomy." However, they also reported that "vision-threatening complications were uncommon (1.0% in MicroShunt vs 0.8% in trabeculectomy)," and hypotony occurred far less often with the MicroShunt (28.9% vs 49.6%).

Complication	PreserFlo (%)	Trabeculectomy (%)
Transient hypotony	28.9	49.6
Shallow/flat anterior chamber	3.8	8.0
Bleb leak	3.2	5.3
Hypotony maculopathy	0	1.5
Endophthalmitis	0	0.4

Although trabeculectomy achieved a slightly lower mean IOP (11.1 mmHg vs 14.3 mmHg), PreserFlo reduced the frequency and severity of postoperative complications by nearly half. Khan and Khan (2024) confirmed this statistically, reporting a relative risk of hypotony 0.42 (95 % CI 0.27–0.67) in favor of PreserFlo, while overall qualified success rates were not significantly different between procedures.

These findings establish that PreserFlo sacrifices a few mmHg of pressure for markedly greater safety and a simpler postoperative course—an acceptable trade-off in most clinical situations.

4.3 Comparison with other drainage devices

Traditional glaucoma drainage implants, such as the Ahmed and Baerveldt valves, are designed for refractory or secondary glaucoma and provide excellent pressure reduction, but they are surgically more complex and associated with late complications such as tube erosion, motility restriction, and corneal endothelial loss.

The PreserFlo MicroShunt differs fundamentally. It is an ab externo, valveless implant that relies on the fixed resistance of its 70 μm lumen to maintain steady aqueous flow. It does not require a

plate or reservoir, minimizing foreign-body volume in the orbit. Batlle et al. (2021) described it as "combining the flow-limiting design of a microstent with the outflow characteristics of a filtering bleb." In practice, this means it achieves filtration comparable to a miniature drainage device but with the tissue response profile of a subconjunctival bleb.

The smaller surgical footprint leads to shorter operation time (≈20 minutes) and a shallower learning curve compared with larger shunt devices. Because there is no rigid plate, the risk of erosion or diplopia is negligible. In the long-term follow-up series by Batlle et al. (2021), none of the 23 operated eyes developed erosion, exposure, or motility problems, and endothelial cell loss remained within physiological limits over five years.

Thus, within the hierarchy of surgical invasiveness, the PreserFlo MicroShunt occupies an intermediate position: more effective than MIGS, less invasive and risky than large drainage implants.

4.4 Safety profile

Safety is the defining feature that differentiates the PreserFlo MicroShunt from trabeculectomy and traditional drainage implants. Across all reviewed studies, the rate of transient postoperative events averaged 22 %, while serious or vision-threatening complications remained below 1 %.

The most frequent issue was transient hypotony, which generally resolved within one month without sequelae. Tanner et al. (2023) reported that "all cases of hypotony and choroidal detachment resolved spontaneously." Batlle et al. (2021) confirmed long-term stability: "There were no reports of bleb leaks, chronic hypotony, or endophthalmitis during the five-year follow-up period."

The use of SIBS polymer likely contributes to this safety margin. The material's chemical inertness and smooth surface reduce tissue reaction, fibroblast adhesion, and inflammatory mediator release, which are key factors in both hypotony and bleb failure. The fixed lumen diameter (70 µm) ensures controlled outflow without an internal valve, providing physiological resistance and reducing over-drainage risk.

In both meta-analyses, hypotony was identified as the most common postoperative complication, occurring in 2–39% of cases (Khan & Khan, 2024; Konstantinidis et al., 2024). Despite this, rates of sight-threatening events remain below 1%.

From a patient perspective, this means faster recovery and less postoperative intervention. Fewer needling, suture adjustments, and emergency visits translate into greater comfort and lower health system cost.

4.5 Long-term outcomes

Long-term follow-up supports the durability of the device. Batlle et al. (2021) reported:

"Mean IOP reduction was maintained through five years with an overall success rate of 82.6% and no long-term sight-threatening adverse events."

This durability is particularly important because some minimally invasive devices (e.g., iStent, Hydrus) show gradual regression of efficacy after 2–3 years as episcleral resistance and fibrosis increase. The PreserFlo's bleb-based mechanism appears to maintain filtration more consistently over time, particularly when MMC is used at 0.4 mg/mL.

The revision rate of 10–20 % observed across studies (Tanner 2023; Strzalkowska 2023) should be interpreted as normal maintenance rather than failure. In most cases, a single needling or revision successfully restores bleb function. When compared with reoperation rates for trabeculectomy (15–30 percent within two years), PreserFlo's maintenance burden is actually lower.

4.6 Limitations of current research

Although the results are promising, several limitations must be acknowledged:

1. Short follow-up in many studies: Only one study followed patients beyond five years
2. Variation in MMC concentration: Different protocols (0.2–0.4 mg/mL, 2–5 minutes) make outcomes hard to compare directly
3. Non-standard success definitions: Some studies used 21 mmHg as a cutoff, others 17 or 14 mmHg

4. Patient heterogeneity: Some included pseudoexfoliation or secondary glaucoma cases
5. Lack of cost-effectiveness data: There are limited studies comparing PreserFlo costs with trabeculectomy or tube shunts

Future work should standardize definitions and techniques to improve comparability.

4.7 Practical implications

From a clinical perspective, the PreserFlo MicroShunt provides a predictable, low-risk option for patients with open-angle glaucoma who need surgical pressure control but are unsuitable for or unwilling to undergo trabeculectomy. Its simplicity makes it an appealing first-line surgical choice after medical or laser failure.

In practice, PreserFlo achieves target IOPs in the mid-teens, which are adequate for most moderate glaucomas. For patients with advanced disease requiring single-digit pressures, trabeculectomy or drainage implants remain necessary, but PreserFlo can delay the need for such interventions, preserving ocular surface integrity and conjunctival health for future surgeries.

For surgeons, the PreserFlo MicroShunt offers several practical advantages:

- Shorter operation time and fewer postoperative visits
- Predictable pressure reduction suitable for moderate-to-advanced glaucoma
- Easier learning curve than trabeculectomy
- Safer for patients at risk of hypotony or with thin conjunctiva

However, early follow-up is crucial to identify bleb fibrosis. Prompt needling or open revision can prevent surgical failure.

4.8 Advantages and disadvantages

Advantages	Disadvantages
35–45 % IOP reduction (to 12–15 mmHg)	Slightly higher IOP than trabeculectomy

70–80 % medication reduction	10–20 % needling/revision rate
Fewer serious complications (< 1 %)	Requires MMC use and bleb formation
Shorter surgery and faster recovery	Limited long-term data (> 5 years)
Lower risk of hypotony, infection	Higher device cost vs standard surgery

---

4.9 Future directions

Future studies should aim to:

1. Conduct 10-year prospective trials comparing PreserFlo, trabeculectomy, and valve implants
2. Standardize MMC protocols and postoperative management
3. Develop anti-fibrotic adjuncts to reduce bleb failure
4. Analyze patient-reported outcomes such as visual function and quality of life
5. Assess economic impact to clarify the cost-benefit ratio compared with traditional surgery

Such studies will help position the PreserFlo MicroShunt accurately within glaucoma treatment guidelines.

5 Conclusion

The PreserFlo MicroShunt represents a significant advancement in glaucoma surgery, providing effective intraocular pressure (IOP) control with an improved safety profile. Across randomized, prospective, and long-term studies, it achieves an average IOP reduction of approximately 40%, lowering mean values from 22–24 mmHg to 12–15 mmHg. Medication dependence decreases by 70–80%, with most patients remaining medication-free postoperatively. Compared with trabeculectomy, the MicroShunt yields slightly higher residual IOP but substantially fewer complications and faster recovery. Clinically, it offers a dependable intermediate option between minimally invasive glaucoma surgery (MIGS) and conventional filtration, combining predictable IOP reduction with reduced operative and follow-up demands. Current evidence supports its role as a safe, effective, and durable surgical option for long-term glaucoma management

References

- Baker, N.D., et al., 2021. *Ab-externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma. Ophthalmology,* 128 (12), pp. 1710–1721.
- Beckers, H.J.M., et al., 2021. *Two-year results of PreserFlo MicroShunt implantation in glaucoma. Ophthalmology Glaucoma,* 4 (3), pp. 250–258.
- Batlle, J.F., et al., 2021. *Long-term results of the PreserFlo MicroShunt in primary open-angle glaucoma: Five-year follow-up. Journal of Glaucoma,* 30 (3), pp. 281–286.
- Jamke, M., et al., 2023. *PreserFlo MicroShunt versus Trabeculectomy: A Comparative Prospective Study. Graefe's Archive for Clinical and Experimental Ophthalmology,* 261 (4), pp. 835–845.
- Tanner, A., et al., 2023. *One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: A multicentre analysis. British Journal of Ophthalmology,* 107 (8), pp. 1104–1111.
- Strzalkowska, A., et al., 2023. *Outcomes of open bleb revision after PreserFlo MicroShunt failure in patients with glaucoma. Journal of Glaucoma,* 32 (8), pp. 681–685.
- Khan, A. and Khan, A.U., 2024. *PreserFlo MicroShunt versus trabeculectomy: An updated meta-analysis and systematic review. Acta Ophthalmologica,* 102 (6), pp. 611–620.
- Konstantinidis, A., Pournaras, C.J., Pahlitzsch, M., Tzamalis, A., and Shaarawy, T., 2024. *One-year outcomes of PreserFlo MicroShunt for primary open-angle glaucoma: A systematic review and meta-analysis. Journal of Glaucoma,* 33 (7), pp. 509–518.
- Leske, M.C., *et al.*, 2003. *Factors for glaucoma progression and the effect of treatment: The Early Manifest Glaucoma Trial. Archives of Ophthalmology,* 121 (1), pp. 48–56.

- Heijl, A., *et al.*, 2002. *Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology,* 120 (10), pp. 1268–1279.
- Nobl, M., Grün, C., Kassumeh, S., Priglinger, S. and Mackert, M.J., 2023. *One-year outcomes of Preserflo™ MicroShunt implantation versus trabeculectomy for pseudoexfoliation glaucoma. Journal of Clinical Medicine*, 12(8), p.3000.
- Gedde, S.J., Herndon, L.W., Brandt, J.D., Budenz, D.L., Feuer, W.J. and Schiffman, J.C., 2012. *Postoperative complications in the Tube Versus Trabeculectomy (TVT) Study during five years of follow-up. American Journal of Ophthalmology*, 153(5), pp.804–814.e1.
- Fili, S., Kontopoulou, K., Vastardis, I., Perdikakis, G. & Kohlhaas, M., 2022. *PreserFlo™ MicroShunt versus trabeculectomy in patients with moderate to advanced open-angle glaucoma: 12-month follow-up of a single-centre prospective study.* Cureus, 14(8), e28288.
